A Case of Uveitis and Hypothyroidism Following Pembrolizumab Therapy in a Patient With Plantar Malignant Melanoma

Pembrolizumab is a PD-1 inhibitor that has improved survival in melanoma patients but can cause immune-related adverse events (irAEs) such as hypothyroidism and uveitis. Although these conditions rarely occur together, we present a case of a 54-year-old female with plantar malignant melanoma who developed hypothyroidism after the second cycle of pembrolizumab and then uveitis after the fifth cycle. Hypothyroidism was treated with levothyroxine, and uveitis was managed with corticosteroids. This case highlights the importance of careful monitoring and multidisciplinary management of these adverse events during immunotherapy.